【摘要】 目的:研究DNA修复酶X射线损伤交叉互补蛋白1(X-ray repair cross-complementary protein1,XRCC1)基因Arg399Gln多态性对接受铂类药物辅助化疗的胃癌患者预后的影响。方法:选取经病理学确诊的胃癌患者84例,采用含铂类药物的联合化疗方案进行辅助化疗。化疗前采集患者外周血,采用聚合酶链反应-连接酶检测反应(polymerase chain reaction-ligation detection reaction,PCR-LDR)技术检测XRCC1基因Arg399Gln的多态性。结果:84例胃癌患者中,49例(58.3%)携带XRCC1的399Arg/Arg基因型,30例(35.7%)携带Arg/Gln基因型,5例(6.0%)携带Gln/Gln基因型;截止到随访结束,分别有63.1%(53/84)和55.2%(43/84)的患者出现复发和死亡,其中携带Arg/Arg基因型的胃癌患者复发率和死亡率均显著低于携带Arg/Gln或Gln/Gln基因型患者(P<0.05)。COX多因素分析显示,携带Arg/Arg基因型的患者具有较好的无复发生存期和总生存期预后(P<0.05)。结论:XRCC1Arg399Gln基因多态性与术后胃癌患者接受铂类药物化疗后的预后有关,可以在一定程度上判断术后胃癌患者接受铂类药物化疗的预后情况。更多还原

【Abstract】 Objective:To investigate the association of DNA X-ray repair cross complementary protein 1(XRCC1) Arg399Gln polymorphism with the clinical outcome of gastric cancer patients treated with platinum-based chemotherapy.Methods:Eight-four patients with gastric cancer confirmed by pathological examination received postoperative combined chemotherapy(including platinum).Transcription of XRCC1 Arg399Gln was determined by polymerase chain reaction-ligation detection reaction(PCR-LDR).Results:Of the 84 patients,the frequencies of XRCC1 codon 399 Arg/Arg,Arg/Gln,and Gln/Gln genotype were 58.3%(49/84),35.7%(30/84),and 6.0%(5/84),respectively;and the relapse and death rate were 63.1%(53/84) and 55.2%(43/84),respectively.The relapse and death rates in patients with Arg/Arg genotype were significantly lower than those in patients with Arg/Gln or Gln/Gln genotypes(P<0.05).COX multivariate analysis showed that XRCC1 Arg399Arg polymorphism was associated with better recurrence-free and overall survival in gastric cancer patients compared with other genotypes(P<0.05).Conclusion:Polymorphism of XRCC1 Arg399Gln correlated with the prognosis of gastric cancer patients treated with postoperative platinum-based chemotherapy.It may be helpful to a certain extent for evaluating the prognosis.更多还原